Background-The biological response to antiplatelet drugs has repeatedly been shown to predict the recurrence of major adverse cardiovascular events (MACEs). However, most studies involved coronary artery disease patients with recent vessel injury shortly after the initiation of antiplatelet therapy. Data on stable cardiovascular patients are scarce, and the added predictive value of specific assays (the vasodilator phosphoprotein assay for the clopidogrel response and serum thromboxane B2 for the aspirin response) and aggregation-based assays relative to common predictors has rarely been addressed.
A ntiplatelet drugs are part of the first-line treatment for atherothrombosis. 1 The benefit of low-dose aspirin in cardiovascular patients is related to permanent inactivation of cyclooxygenase-1 and subsequent inhibition of thromboxane (Tx) A2 production, whereas clopidogrel and other anti-P2Y 12 drugs target the platelet ADP amplification pathway by inhibiting P2Y 12 receptor function. 2 Biological antiplatelet drug responsiveness is highly variable and has been linked to cardiovascular outcome in patients treated with aspirin or clopidogrel. High on-treatment platelet reactivity (HPR) is reported to be predictive of ischemic events, with relative risks ranging from 2 to 4 in meta-analyses of studies involving mainly patients with acute vessel injury after acute coronary syndromes or percutaneous coronary interventions and shortly after initiation of antiplatelet drug treatment. [3] [4] [5] In addition, although several studies have shown that platelet reactivity may vary during the first days of antiplatelet drug treatment, 6, 7 biological evaluation of platelet function was usually performed only once.
Assays used to evaluate antiplatelet drug responsiveness differ by their specificity for the targets of aspirin and clopidogrel. Quantification of serum TxB2, the stable breakdown product of TxA2, and quantification of the phosphorylation status of the vasodilator phosphoprotein (VASP assay) are highly specific for platelet-derived TxA2 inhibition by aspirin and P2Y 12 receptor inhibition by clopidogrel, respectively. 8 The terms poor aspirin responsiveness and poor clopidogrel responsiveness are used here with respect to these specific assays. Aggregation-based assays such as the Platelet Function Analyzer-100 (PFA-100) and agonist-induced platelet aggregation tests tend to be less specific for antiplatelet drug targets and thus provide a more global assessment of platelet reactivity. The term HPR relates more to these nonspecific assays. To the best of our knowledge, there are no data on the predictive value of specific and less specific platelet function assays performed in the same population of stable cardiovascular patients treated with aspirin and/or clopidogrel at distance from acute vessel injury.
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In this prospective multicenter study of 771 consecutive stable cardiovascular outpatients treated with aspirin and/ or clopidogrel, we examined whether specific and/or aggregation-based platelet function assays had added predictive value for major adverse cardiovascular events (MACEs) relative to common predictors.
Methods

Study Population
The study population has been described in detail elsewhere. 9 Briefly, the Antiplatelet Drug Resistances and Ischemic Events (ADRIE; http://www.clinicaltrials.gov; unique identifier NCT00501423) is a prospective study focusing on the clinical relevance of the platelet response to aspirin and/or clopidogrel in stable cardiovascular patients. Between June 2006 and December 2008, consecutive patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease) treated with non-enteric-coated aspirin and/or clopidogrel for Ͻ5 years were included.
The patients attended a first outpatient visit at least 1 month after the last acute ischemic event and at least 10 days after any nonsteroidal anti-inflammatory drug intake for a physical examination and blood sampling. Laboratory analyses included platelet function tests. The patients were specifically questioned on adherence to treatment during a face-to-face interview. Patients who omitted at least 1 dose of either antiplatelet drug at least once a week were designated as noncompliant. The patients attended a second outpatient visit between 1 and 3 months after the first visit for the same platelet function tests.
The patients gave their written informed consent, and the study protocol was approved by the Central Ethics Committee of the University Hospitals of Geneva (Geneva center) and the Ethics Committee of Montpellier Saint-Eloi (Béziers and Montpellier centers).
Aspirin-and Clopidogrel-Specific Assays
Blood Collection
Venous blood was collected in resting (Ͼ15 minutes) patients after an overnight fast with a 21-gauge needle and no tourniquet in tubes containing EDTA, lithium heparin, 0.105 mol/L sodium citrate (1 vol/9 vol), or no anticoagulant (BD Vacutainer, Becton Dickinson, Meylan, France).
Evaluation of Platelet-Derived TxA2 Production and Definition of Poor Aspirin Responsiveness
TxA2 production in response to endogenous thrombin was evaluated by allowing a 6-mL tube of whole blood to clot at 37°C for 1 hour as previously described. 10 Serum was stored at Ϫ80°C, and TxB2, the stable breakdown product of TxA2, was assayed within 3 months after collection with an ELISA kit for TxB2 (GE Healthcare, Glattbrugg, Switzerland) by researchers blinded to all other test results. TxB2 assay was performed with 2 dilutions, each in duplicate, and samples with a coefficient of variation of Ͼ8% were retested. TxB2 assay was centralized and performed by the same technician in Geneva. Values at the first and second outpatient visits were averaged for analysis. There is no validated cutoff for poor aspirin responsiveness based on TxB2 serum levels. 11 To define a cutoff above which patients would be identified as poor aspirin responders, the study protocol specified the use of a receiveroperating characteristics (ROC) curve-based procedure after 3 years of follow-up. The ROC curve approach allows one to assess the overall prognostic value of an assay and to derive an optimal cutoff. To avoid overfitting of the present data, the protocol also specified the use of a cutoff derived from previous data, again with the use of an ROC curve approach; these previous data were derived from 2 independent populations, and both identified a TxB2 cutoff of Ն12 ng/mL. 12, 13 
Evaluation of P2Y 12 Receptor Inhibition and Definition of Poor Clopidogrel Responsiveness
VASP phosphorylation status and the platelet reactivity index (PRI) were evaluated with citrated blood and a standardized assay (platelet VASP/P2Y 12 , Biocytex, Marseille, France) 14 on a FACStrack flow cytometer (Becton Dickinson) within 24 hours after blood collection. Flow cytometry was performed in 2 centers (Montpellier for patients recruited in Béziers and Montpellier, Geneva for other patients) with reagents from the same batch following the manufacturer's instructions. Values at the first and second outpatient visits were averaged for analysis. The protocol specified the use of an ROC curve after 3 years of follow-up to derive the optimal cutoff for poor clopidogrel responsiveness. To assess potential overfitting of the present data, the protocol also specified the use of the conventional PRI cutoff of Ն50%. 9, 15 
Aggregation-Based Assays and Definition of HPR
Platelet Aggregation
Platelet aggregation was evaluated in citrated platelet-rich plasma adjusted to 250 G/L platelets with autologous platelet-poor plasma on an 8-channel aggregometer (TA-8V, SD Medical, Heillecourt, France) using one of the following agonists: arachidonic acid 1 mmol/L (Bio/Data Corp, Horsham, PA), ADP 5 and 20 mol/L (Sigma-Aldrich, Buchs, Switzerland), or Horm collagen 1 g/mL (Nycomed, Linz, Austria). The aggregation procedure was performed within 3 hours after blood collection. Reagents were from the same batches; the same aggregometer models were used by all the centers; and training sessions were conducted in each center to ensure that standardized operating procedures were applied uniformly. Aggregation values at the first and second outpatient visits were averaged for analysis.
The PFA-100
The PFA-100 (Siemens, Marburg, Germany) is a Food and Drug Administration-approved device usually used to evaluate acquired and congenital platelet dysfunction. 16 The PFA-100 device measures the time (closure time) required for platelets to plug an aperture simulating an injured vessel after platelet activation by relevant stimuli, namely collagen and epinephrine or collagen and ADP. The maximum possible closure time is 300 seconds, and values Ͼ300 seconds correspond to nonclosure.
Definition of HPR
To define HPR for each aggregation-based assay, the protocol specified the use of an ROC curve to derive optimal cutoffs after 3 years of follow-up. To assess potential overfitting of the present data, the protocol also specified the use of cutoffs from previous studies as follows: maximal aggregation Ն20% with arachidonic acid as the agonist, 17 maximal aggregation Ն90th percentile of the distribution with collagen 1 g/mL, 18 and maximal aggregation Ն55% with ADP 20 mol/L and Ն42% with ADP 5 mol/L. These last 2 cutoffs were derived from ROC curves constructed in a meta-analysis of individual patient data. 19 Finally, data from a meta-analysis of prospective studies and from recent studies suggested a cutoff of Ͻ190 seconds for the PFA-100 collagen and epinephrine cartridge. 4, 20 The biologists were blinded to the patients' clinical status.
Clinical Outcomes
Follow-Up and Clinical End Points
The primary outcome was the first occurrence of a MACE composite end point (acute myocardial infarction, unstable angina, hospitaliza-tion for revascularization, acute limb ischemia, ischemic stroke, transient ischemic attack, or cardiovascular death). Patients were contacted by telephone every 6 months, with specific questions on cardiovascular symptoms, any illness, hospitalization for any reason, and compliance. Any stated change in health status prompted further investigations with the regular physician and/or in the hospital. Hospital reports were retrieved for each admission. Causes of death were established from the medical records. Patients were deemed lost to follow-up when they could not be contacted after 6 telephone calls on different days, if their treating physician had not seen them for Ͼ6 months, if there was no admission to the city hospital during the last 6 months, and if they did not respond to a letter sent to their last known address. The clinicians were blinded to all platelet function test results.
Adjudicating Committee
An independent adjudicating committee was commissioned (N. Danchin, MD, PhD, Cardiology Department, and J.-N. Fiessinger, MD, Vascular Medicine Department, Hôpital Européen Georges Pompidou, Paris, France; E. Touzé, MD, PhD, Stroke Unit, Neurology, Hôpital Saint-Anne, Paris, France). The adjudicating committee members had access to all reports on clinical events and were blinded to the patients' treatment and platelet function test results.
Statistical Analysis
The study was designed to detect a relative risk of 2 for the occurrence of MACEs associated with poor aspirin and/or clopidogrel responsiveness. Assuming an annual MACE incidence of 5% and a rate of poor responsiveness of 10%, we determined that 730 CAD indicates coronary artery disease; PAD, peripheral artery disease; ICD, ischemic cerebrovascular disease; LDL, low-density lipoprotein; BMI, body mass index; ACE, angiotensin-converting enzyme; PPI, proton pump inhibitors; and CRP, C-reactive protein.
patients would be necessary (␣ϭ0.05 and ␤ϭ0.20). Target recruitment was initially set at 800 to anticipate losses to follow-up.
The first aim of the main survival analysis was to identify demographic factors independently associated with the occurrence of MACEs. All mutually unrelated factors with univariate log-rank values of PϽ0.20 and common vascular risk factors and sex, regardless of their P values, were included in a multivariate Cox model. A backward stepwise selection procedure was used 21 to remove variables until all covariates had a value of PϽ0.1. Overall prognostic value was expressed with the C-index of the final Cox model. In the second part of the main analysis, Kaplan-Meier and log-rank methods were used to evaluate the prognostic value of platelet responsiveness (poor responsiveness and HPR evaluated with specific and nonspecific tests, respectively) using ROC curvederived optimal cutoffs and literature-based cutoffs. In the ROC curve-derived optimal cutoffs, we focused on derivation of possible cutoffs that will predict the MACE by optimizing the sensibility and specificity. Poor responsiveness or HPR was then added to the multivariate Cox model, and the c value of the model was updated.
Prespecified secondary and post hoc sensitivity analyses included (1) survival analyses restricted to subgroups of coronary artery disease, peripheral artery disease, and ischemic cerebrovascular disease patients; (2) survival analyses of patients with poor responses to both aspirin and clopidogrel compared with the rest of the population; (3) time-dependent ROC curves 22 to determine whether the prognostic value of poor aspirin or clopidogrel responsiveness changed during follow-up; and (4) survival analyses excluding patients who switched to a different antiplatelet drug regimen or were deemed noncompliant during follow-up.
Data are reported as meanϮSD or as medians and interquartile interval. Categorical variables are expressed as percentages. The correlation between visit 1 and visit 2 platelet function test results was evaluated with the intraclass correlation coefficient. Data were analyzed with R software, version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria; www.R-project.org). Statistical significance was assessed at the 0.05 level for all analyses. Table 1 summarizes the characteristics of the population, both overall and according to antiplatelet drug therapy. Mean age was 62.9 years, and 19% of the patients were women. None of the patients had acute vessel injury Ͻ1 month before the first platelet function tests. Figure 1 shows the study flowchart. The first platelet function tests were performed a median of 59 days (interquartile interval, 38 -520 days) after acute vessel injury (acute ischemic event or revascularization) present in 523 patients, where as the remaining 248 were patients with symptomatic and documented atherothrombosis but no prior acute ischemic events or revascularization. Platelet function test results were available for Ͼ99.5% of the population, and Ͻ1% of the patients (nϭ6) were lost to follow-up during the 3-year study period, allowing survival analyses to be conducted on Ͼ99% of the population. Median follow-up was 36.5 months. The median time between the 2 outpatient visits (and the platelet function tests) was 56 days (interquartile interval, 37-63 days). There was a good correlation between the results of the different tests at the first and second outpatient visits, with intraclass coefficients of 0.86, 0.81, 0.71, 0.81, 0.67, 0.68, and 0.59 for TxB2, VASP-PRI, collagen, arachidonic acid, ADP 5 and ADP 20 mol/L aggregation, and PFA-100, respectively (PϽ0.001).
Results
Patient Demographics
Clinical Outcomes
MACEs were observed in 15.6% of the patients (Table 2 ) and consisted mostly of acute ischemic events. MACEs occurred a median of 15 months (interquartile interval, 5-26 months) after inclusion in the study. Roughly half of the events (nϭ57) occurred in patients with a history of acute ischemic events a median of 24 months after the most recent event; the remainder occurred in patients who had symptomatic atherosclerotic disease but no history of acute ischemic events.
Demographic Factors and MACEs
Individual factors associated with MACEs were identified by univariate survival analysis (Table 3 ). Variables with values of PϽ0.2, together with conventional risk factors and sex, were then included in a Cox model followed by stepwise selection, generating a model that retained all variables with values of PϽ0.1; Table 4 ), namely hypertension, smoking, older age, and elevated low-density lipoprotein cholesterol. The C-index, expressing the predictive value of the model, was 0.63.
Poor Antiplatelet Drug Response and MACEs
No cutoff could be derived because the areas under the ROC curves for serum TxB2 (0.46; 95% confidence interval [CI], 0.38 -0.55) and VASP-PRI (0.52; 95% CI, 0.45-0.59]) in patients treated with aspirin and clopidogrel, respectively, were not significantly different from 0.5 ( Figure I in the online-only Data Supplement). Literature-based cutoffs were therefore used for survival analysis. During follow-up, 15% of the patients (57 of 372) with a poor response to at least 1 antiplatelet drug (serum TxB2 Ն12 ng/mL and/or VASP-PRI Ն50%) experienced a MACE compared with 16% of the patients (63 of 397) with no poor response to either antiplatelet drug. As shown in Figure 2A , MACE-free survival was not different between patients with and without at least 1 poor response (univariate log-rank Pϭ0.70). Addition of poor response status to the multivariate Cox model followed by stepwise selection had no significant influence, and the predictive value of the overall model 2 (demographics plus poor response in specific tests) remained unchanged compared with model 1 ( Table 4 ). Analyses restricted to poor aspirin response in patients treated with aspirin and to poor clopidogrel response in patients treated with clopidogrel yielded similar results ( Figure 2B and 2C ).
HPR and MACEs
As with the specific assays, none of the areas under the ROC curves for the different aggregation-based assays performed in the overall population were significantly different from 0.5, precluding the selection of cutoffs to define HPR ( Figure  I in the online-only Data Supplement). The cutoffs were therefore based on published data. The frequency of MACE is reported in Table 3 according to the different cutoffs for each assay, and the corresponding Kaplan-Meier curves are shown in Figure 3 . MACE-free survival was not influenced by the results of any of the assays (univariate log-rank Pϭ0.14 -0.91). When the tests were included individually in the (Table 4 ) was unchanged compared with model 1.
Prespecified Secondary and Post Hoc Sensitivity Analyses
MACE-free survival analysis according to responsiveness in specific tests and to HPR in aggregation-based assays gave similar results in coronary artery disease patients (nϭ511), peripheral artery disease patients (nϭ163), and ischemic cerebrovascular disease patients (nϭ97), with all log-rank P values being nonsignificant.
In the group of patients treated with both aspirin and clopidogrel (nϭ422), MACE-free survival was not significantly different for patients with only 1 good response (to either aspirin or clopidogrel; nϭ199; hazard ratio [HR], 0.94; 95% CI, 0.51-1.76) and for patients with a good response to both aspirin and clopidogrel (nϭ147; HRϭ0.87; 95% CI, 0.44 -1.69) compared with patients with poor responses to both drugs (nϭ76).
Time-dependent ROC curves were used to assess possible changes during follow-up in the predictive value of specific and aggregation-based assays for MACEs regardless of the predefined cutoffs. The areas under the curve ranged from 0.46 to 0.58 for serum TxB2 and from 0.49 to 0.58 for VASP-PRI and were never significantly higher than 0.5 at any point of follow-up for either specific or aggregationbased assays.
Because atherosclerotic risk factors such as diabetes mellitus and sex are known to influence platelet response to antiplatelet drugs, 9, [23] [24] [25] we tested the hypothesis of an interaction between these factors and poor response to aspirin or clopidogrel. The addition of an interaction factor in the multivariate analysis (on top of model 1) did not modify the overall results; the HRs were 1.06 (95% CI, 0.36 -3.17; Pϭ0.91) and 0.40 (95% CI, 0.13-1.29; Pϭ0.13) for the interaction with diabetes mellitus and sex, respectively, in aspirin-treated patients. Similarly, the HRs were 1.38 (95% CI, 0.46 -4.18; Pϭ0.57) and 1.72 (95% CI, 0.48 -6.14; Pϭ0.41) for the interaction with diabetes mellitus and sex, respectively, in clopidogrel-treated patients.
Similar results were obtained when we excluded from multivariate analysis the 20 patients who switched to a different antiplatelet drug regimen during follow-up (poor response in specific tests: HR, 1.03; 95% CI, 0.71-1.49; Pϭ0.89; and, eg, HPR with collagen: HR, 0.54; 95% CI, 0.25-1.16; Pϭ0.11). Finally, similar results were obtained when the 31 patients identified as having poor compliance during follow-up by questionnaire-based interview were excluded from the analysis.
Discussion
Although the biological response to antiplatelet drugs has repeatedly been shown to predict the recurrence of MACEs, in most studies, platelet function was generally assessed only once with assays that were not specific for the antiplatelet drugs received. In addition, the assays were often performed shortly after percutaneous coronary intervention and initiation of antiplatelet drug treatment. The present study evaluated platelet function in a population of stable cardiovascular outpatients using both specific and aggregation-based assays to assess both aspirin and clopidogrel potencies. (14) MACE indicates major adverse cardiovascular events; CAD, coronary artery disease; PAD, peripheral artery disease; ICD, ischemic cerebrovascular disease; CRP, C-reactive protein; TxB2, thromboxane B2; VASP-PRI, vasodilator phosphoprotein platelet reactivity index; AA, arachidonic acid; ADP, adenosine diphosphate; PFA-100, Platelet Function Analyzer-100; and CEPI, collagen and epinephrine. Our main finding is that neither specific nor aggregationbased assays of antiplatelet drug responsiveness add significant predictive value relative to conventional risk factors for the recurrence of ischemic events in stable cardiovascular patients. These results are in keeping with those of recent data on aspirin responsiveness in stable cardiovascular patients treated with aspirin alone. 26, 27 They contrast, however, with studies of other populations, including acute patients and/or patients assessed for platelet reactivity Ͻ1 month after treatment initiation, usually after percutaneous coronary interventions. [3] [4] [5] 28, 29 In their study of 562 patients (22% with acute coronary syndromes) undergoing percutaneous coronary interventions, Frelinger et al 20 found that serum TxB2 was not significantly associated with MACEs in univariate analysis but multivariate logistic regression gave a significant HR of 2.22 (95% CI, 1.21-4.1).
Platelet activation is modulated by inflammatory processes associated with acute thrombotic events such as increased expression or secretion of prothrombotic and proinflammatory mediators, including CD40L, P-selectin, and nuclear factor-B. 30, 31 A study of 102 consecutive patients undergoing cardiac catheterization for chest pain revealed a marked elevation of nuclear factor-B levels in patients with unstable angina but not in patients with stable angina. 32 Platelet activation enhances platelet adhesion to leukocytes (mainly monocytes and neutrophils), a process mediated primarily by platelet P-selectin binding to its glycoprotein ligand-1 on leukocytes. 30 It is conceivable that poor antiplatelet drug responsiveness and HPR have a greater influence on clinical outcome during or shortly after an acute ischemic event or shortly after stent implantation owing to interplay between activated platelets and ruptured plaque or the stent strut. Conversely, poor antiplatelet drug response and HPR may be less critical in stable cardiovascular patients owing to lower endothelial thrombogenicity 32, 33 and lower platelet activation status. 34 Specific assays may not be as sensitive as aggregation-based assays to the inflammation associated with acute ischemic events. The differences in platelet reactivity assessment between specific and aggregation-based assays are further supported by the marked heterogeneity evidenced in meta-analysis of studies using various platelet function assays. 3, 29 This heterogeneity may also be explained by the use of different cutoffs to define HPR and by differences in the prevalence of HPR across studies. 5 Although the prevalence of poor clopidogrel response is relatively homogeneous with a common cutoff in most studies, 15 the prevalence of poor aspirin response is more debated and highly dependent on the cutoff value. 11 The strengths of the present study include the multicenter design, evaluation of platelet function on 2 separate occasions, assessment of clinical end points by an independent adjudicating committee, and very low rate of loss to followup. Moreover, treatment adherence was excellent, possibly because the patients were more aware of the importance of 2 . Kaplan-Meier major adverse cardiovascular event (MACE)-free survival curves for patients with at least 1 poor response (resp.) to aspirin or clopidogrel in specific assays (thromboxane B2 [TxB2] Ն12 ng/mL and/or vasodilator phosphoprotein platelet reactivity index [VASP-PRI] Ն50%) vs patients with no poor specific responses (A); for aspirin-treated patients (nϭ659) with a poor specific response to aspirin (TxB2 Ն12 ng/mL) vs aspirin-treated patients with no poor specific response to aspirin (B); and for clopidogreltreated patients (nϭ534) with a poor specific response to clopidogrel (VASP-PRI Ն50%) vs clopidogrel-treated patients with no poor specific response to clopidogrel (C).
antiplatelet drug treatment, given the stated focus of the study. In the recently published Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing Elective PCI study (POPULAR), 35 Ͼ95% of patients remained compliant to their antiplatelet drug treatment 6 months after enrollment, as assessed by pharmacy refill data. Evaluation of platelet function on 2 separate occasions is of particular importance in that several studies have shown that the biological potency of antiplatelet drugs can vary after treatment initiation 6, 7 and that variations are minimal after 1 month. 36 Our data are in line with these previous findings on the stability of platelet function test results between visits 1 and 2, further supporting the stable status of our patients. Although this was not an epidemiological study designed to identify traditional risk factors, we confirmed that older age, smoking, and hypertension or low-density lipoprotein levels above recommended targets were predictive of MACEs (overall predictive value, 0.63), in line with other studies in similar settings. 35 One limitation of this study is that we did not use a number of available biological tests (eg, VerifyNow, PFA-100 collagen and ADP, and the Multiplate assay) and cannot extrapolate our findings or assume that other measures of platelet function might not offer predictive value among patients with stable cardiovascular disease. However, we used both specific and aggregation-based assays, the latter (light transmission aggregometry) being widely used in clinical studies and considered the historic gold standard for the evaluation of platelet function. Moreover, this study had 80% power to detect a relative risk of Ն1.7 associated with a poor response to aspirin and a relative risk of Ն1.8 associated with a poor response to clopidogrel. The clinical significance of relative risks below these limits is questionable. The ADRIE study has the limitations inherent to all observational studies. However, its design was similar to that of most previous studies that showed an association between platelet reactivity and cardiovascular events. Such real-life studies ideally represent the setting in which patients are tested for their biological response to antiplatelet agents. Finally, the ADRIE study was not powered to address the primary end point in each cardiovascular subgroups, and replication of the overall findings in independent cohorts is warranted.
Conclusions
The ADRIE study provides new evidence that, in stable cardiovascular outpatients, neither specific nor aggregation-based assays of antiplatelet drug responsiveness add any incremental predictive value, relative to common cardiovascular risk factors, for the occurrence of MACEs. These results do not support platelet function testing for MACE risk evaluation in stable cardiovascular outpatients. 
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